comparemela.com
Latest Breaking News On - Durable clinical benefit - Page 1 : comparemela.com
Keros Therapeutics, Inc. Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition
Keros Therapeutics, Inc. announced that it presented additional data from its two ongoing Phase 2 clinical trials of KER-050, one in patients with very low-, low-, or intermediate-risk myelodysplastic.
San-diego
California
United-states
American
American-society-of-hematology
Keros-therapeutics-inc
Keros-therapeutics
American-society
Annual-meeting
Durable-clinical-benefit
Findings-from
vimarsana © 2020. All Rights Reserved.